Abexinostat has been used in trials studying the treatment of Sarcoma, Lymphoma, Leukemia, Lymphocytic, and Hodgkin Disease, among others. It is a novel, broad-spectrum hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Ivabradine | Ivabradine may increase the QTc-prolonging activities of Abexinostat. |
| Vorinostat | The risk or severity of gastrointestinal bleeding and thrombocytopenia can be increased when Abexinostat is combined with Vorinostat. |
| Dofetilide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Dofetilide. |
| Citalopram | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Citalopram. |
| Anagrelide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Anagrelide. |
| Disopyramide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Disopyramide. |
| Clemastine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Clemastine. |
| Ibutilide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Ibutilide. |
| Valproic acid | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Valproic acid. |
| Terfenadine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Terfenadine. |
| Grepafloxacin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Grepafloxacin. |
| Quinine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Quinine. |
| Sotalol | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Sotalol. |
| Erlotinib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Erlotinib. |
| Toremifene | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Toremifene. |
| Cisapride | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Cisapride. |
| Imatinib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Imatinib. |
| Astemizole | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Astemizole. |
| Thioridazine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Thioridazine. |
| Trovafloxacin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Trovafloxacin. |
| Mifepristone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Mifepristone. |
| Cocaine | The risk or severity of methemoglobinemia can be increased when Abexinostat is combined with Cocaine. |
| Quinidine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Quinidine. |
| Procainamide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Procainamide. |
| Pimozide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Pimozide. |
| Amiodarone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Amiodarone. |
| Arsenic trioxide | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Arsenic trioxide. |
| Escitalopram | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Escitalopram. |
| Domperidone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Domperidone. |
| Sparfloxacin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Sparfloxacin. |
| Halofantrine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Halofantrine. |
| Bepridil | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Bepridil. |
| Paliperidone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Paliperidone. |
| Lithium cation | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Lithium cation. |
| Temafloxacin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Temafloxacin. |
| Zuclopenthixol | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Zuclopenthixol. |
| Tetrabenazine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Tetrabenazine. |
| Dronedarone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Dronedarone. |
| Nilotinib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Nilotinib. |
| Iloperidone | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Iloperidone. |
| Vandetanib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Vandetanib. |
| Romidepsin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Romidepsin. |
| Asenapine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Asenapine. |
| Artemether | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Artemether. |
| Lumefantrine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Lumefantrine. |
| Vemurafenib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Vemurafenib. |
| Eliglustat | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Eliglustat. |
| Ribociclib | The risk or severity of QTc prolongation can be increased when Ribociclib is combined with Abexinostat. |
| Glasdegib | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Glasdegib. |
| Deutetrabenazine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Deutetrabenazine. |
| Macimorelin | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Macimorelin. |
| Terodiline | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Terodiline. |
| Leuprolide | The risk or severity of QTc prolongation can be increased when Leuprolide is combined with Abexinostat. |
| Goserelin | The risk or severity of QTc prolongation can be increased when Goserelin is combined with Abexinostat. |
| Erythromycin | The risk or severity of QTc prolongation can be increased when Erythromycin is combined with Abexinostat. |
| Azithromycin | The risk or severity of QTc prolongation can be increased when Azithromycin is combined with Abexinostat. |
| Moxifloxacin | The risk or severity of QTc prolongation can be increased when Moxifloxacin is combined with Abexinostat. |
| Ranolazine | The risk or severity of QTc prolongation can be increased when Ranolazine is combined with Abexinostat. |
| Sulfisoxazole | The risk or severity of QTc prolongation can be increased when Sulfisoxazole is combined with Abexinostat. |
| Amitriptyline | The risk or severity of QTc prolongation can be increased when Amitriptyline is combined with Abexinostat. |
| Methadone | The risk or severity of QTc prolongation can be increased when Methadone is combined with Abexinostat. |
| Diltiazem | The risk or severity of QTc prolongation can be increased when Diltiazem is combined with Abexinostat. |
| Clozapine | The risk or severity of QTc prolongation can be increased when Abexinostat is combined with Clozapine. |
| Sulpiride | The risk or severity of QTc prolongation can be increased when Sulpiride is combined with Abexinostat. |
| Nimodipine | The risk or severity of QTc prolongation can be increased when Nimodipine is combined with Abexinostat. |
| Promazine | The risk or severity of QTc prolongation can be increased when Promazine is combined with Abexinostat. |
| Prochlorperazine | The risk or severity of QTc prolongation can be increased when Prochlorperazine is combined with Abexinostat. |
| Droperidol | The risk or severity of QTc prolongation can be increased when Droperidol is combined with Abexinostat. |
| Imipramine | The risk or severity of QTc prolongation can be increased when Imipramine is combined with Abexinostat. |
| Chlorpromazine | The risk or severity of QTc prolongation can be increased when Chlorpromazine is combined with Abexinostat. |
| Oxaliplatin | The risk or severity of QTc prolongation can be increased when Oxaliplatin is combined with Abexinostat. |
| Ciprofloxacin | The risk or severity of QTc prolongation can be increased when Ciprofloxacin is combined with Abexinostat. |
| Fluorouracil | The risk or severity of QTc prolongation can be increased when Fluorouracil is combined with Abexinostat. |
| Perflutren | The risk or severity of QTc prolongation can be increased when Perflutren is combined with Abexinostat. |
| Cinnarizine | The risk or severity of QTc prolongation can be increased when Cinnarizine is combined with Abexinostat. |
| Atropine | The risk or severity of QTc prolongation can be increased when Atropine is combined with Abexinostat. |
| Chloroquine | The risk or severity of QTc prolongation can be increased when Chloroquine is combined with Abexinostat. |
| Efavirenz | The risk or severity of QTc prolongation can be increased when Efavirenz is combined with Abexinostat. |
| Adenosine | The risk or severity of QTc prolongation can be increased when Adenosine is combined with Abexinostat. |
| Pentamidine | The risk or severity of QTc prolongation can be increased when Pentamidine is combined with Abexinostat. |
| Gadobenic acid | The risk or severity of QTc prolongation can be increased when Gadobenic acid is combined with Abexinostat. |
| Carbinoxamine | The risk or severity of QTc prolongation can be increased when Carbinoxamine is combined with Abexinostat. |
| Dolasetron | The risk or severity of QTc prolongation can be increased when Dolasetron is combined with Abexinostat. |
| Roxithromycin | The risk or severity of QTc prolongation can be increased when Roxithromycin is combined with Abexinostat. |
| Nalidixic acid | The risk or severity of QTc prolongation can be increased when Nalidixic acid is combined with Abexinostat. |
| Cinoxacin | The risk or severity of QTc prolongation can be increased when Cinoxacin is combined with Abexinostat. |
| Loperamide | The risk or severity of QTc prolongation can be increased when Loperamide is combined with Abexinostat. |
| Granisetron | The risk or severity of QTc prolongation can be increased when Granisetron is combined with Abexinostat. |
| Ondansetron | The risk or severity of QTc prolongation can be increased when Ondansetron is combined with Abexinostat. |
| Levosimendan | The risk or severity of QTc prolongation can be increased when Levosimendan is combined with Abexinostat. |
| Mesoridazine | The risk or severity of QTc prolongation can be increased when Mesoridazine is combined with Abexinostat. |
| Desloratadine | The risk or severity of QTc prolongation can be increased when Desloratadine is combined with Abexinostat. |
| Telithromycin | The risk or severity of QTc prolongation can be increased when Telithromycin is combined with Abexinostat. |
| Lomefloxacin | The risk or severity of QTc prolongation can be increased when Lomefloxacin is combined with Abexinostat. |
| Dimenhydrinate | The risk or severity of QTc prolongation can be increased when Dimenhydrinate is combined with Abexinostat. |
| Primaquine | The risk or severity of QTc prolongation can be increased when Primaquine is combined with Abexinostat. |
| Papaverine | The risk or severity of QTc prolongation can be increased when Papaverine is combined with Abexinostat. |
| Chlorpheniramine | The risk or severity of QTc prolongation can be increased when Chlorpheniramine is combined with Abexinostat. |
| Nifedipine | The risk or severity of QTc prolongation can be increased when Nifedipine is combined with Abexinostat. |
| Levofloxacin | The risk or severity of QTc prolongation can be increased when Levofloxacin is combined with Abexinostat. |